Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
With thousands of research abstracts and posters being presented at ACR Convergence 2024, Nov. 14–19, at the Walter E. Washington Convention Center in Washington, D.C., figuring out which research is important today, which could prove important in the future, what has the potential to affect clinical care or prove the basis for future research is…
On Sunday, Nov. 17, at ACR Convergence 2024, three speakers will deliver a presentation on Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping. This session will have three 20-minute presentations that cover distinct aspects of RA-associated ILD from early identification of ILD through high-resolution computed tomography (HRCT) text mining, to phenotyping…
As part of the Review Course on Friday Nov. 15 at ACR Convergence 2024, Iain McInnes, MD, will present a session on Challenging Cases in Rheumatoid Arthritis. Case reports represent a healthcare encounter involving a real person with a real clinical problem. They encourage discussions of real-world concerns and experiences, supporting knowledge acquisition and enhancing…
In a study, all doses of LEVI-04 demonstrated significant pain relief for patients with knee osteoarthritis compared with placebo.
The FDA accepted a new drug application for suzetrigine, a non-opioid analgesic, based on the results from clinical trials in patients with neuropathy and those post-surgery.
Celebrating its long history, the Division of Rheumatology & Immunology at Medical University of South Carolina has made strides in scleroderma, lupus and more.
In this episode, Dr. Kumar tackles issues from the dual perspectives of a clinician who also happens to have inflammatory arthritis.